Agilent Technologies 2014 Early Career Professor Award Supports Biomedical Research at the Broad Institute
Dr. Paul Blainey Recognized for Work in Single-Cell Measurement, Analysis
SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today announced that Paul Blainey, Ph.D., assistant professor in the Massachusetts Institute of Technology (MIT) Department of Biological Engineering and a researcher at the Broad Institute, is the recipient of Agilent's sixth annual Early Career Professor Award for his work in single-cell measurement and analysis.
Blainey's research focuses on integrating new microfluidic, optical and molecular tools into biological research and medicine. His lab develops quantitative single-cell and single-molecule approaches that reveal the workings of natural and engineered biological systems across a range of scales.
Recently, Blainey demonstrated that DNA-binding proteins track the DNA helix as they slide and discovered new classes of biomolecules with sliding activity. Ongoing studies using microfluidic single-molecule assays will help understand how these molecules move; they will also identify additional classes of biomolecules that use thermal energy to move in both directions along a strand of DNA.
'Our department is very proud to have Paul Blainey receive this highly competitive award from Agilent, a company that has played a leading role in biotechnology for many years,' said Douglas Lauffenburger, Ford Professor of Biological Engineering, Chemical Engineering and Biology, and head of MIT's Department of Biological Engineering. 'Paul is a splendidly meritorious awardee, based on his superb accomplishments and exceptional promise for continuing impact in single-cell measurement and analysis technologies.'
'Dr. Blainey's groundbreaking research in single-cell measurement puts him at the forefront of a very talented group of scientists from around the world,' said Jack Wenstrand, director of University Relations and External Research at Agilent. 'We are proud to support his promising career with this award.'
The Agilent Early Career Professor Award is presented annually to recognize and encourage excellence in measurement research. It seeks to establish strong collaborative relationships between Agilent researchers and leading professors early in their careers, as well as to underscore Agilent's role as a sponsor of university research.
More details are available at www.agilent.com/univ_relation/profaward/index.shtml.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
-
Most popular related searches
Related news
-
Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers
Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. Exosomes are considered to be a new and effective intercellular communication carrier. Adjacent cells or distant cells...
-
Creative Proteomics Offers Untargeted Metabolomics Service for Academia and Various Industries
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation in providing contract services specialized for metabolomics. Recently, the company announced the untargeted metabolomics service, which is a powerful tool for large-scale early phase diagnosis and...
-
Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing and collaboration center in leased space on UCSF`s Mission Bay campus, which includes biomedical research facilities...
-
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Inflammatix a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, to further develop its point-of-care test and system to diagnose infection by reading the immune system. The contract is part of a BARDA contract worth up to $72 million, if all options are exercised. The...
-
Thermo Fisher Scientific`s Response to COVID-19 Continues to Expand to Support Development and Production of Therapeutics and Vaccines
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally. "Well before the pandemic, we were strategically investing in capacity and capabilities to increase manufacturing...
Customer comments
No comments were found for Agilent Technologies 2014 Early Career Professor Award Supports Biomedical Research at the Broad Institute. Be the first to comment!